Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.69 |
| ▸ | ESR1 | P03372 | 4/20 | 0.68 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.68 |
| ▸ | SHBG | P04278 | 1/20 | 0.64 |
| ▸ | STS | P08842 | 2/20 | 0.55 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | G6PD | P11413 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | DAB2IP | Q5VWQ8 | 1/20 | 0.49 |
| ▸ | ADCY10 | Q96PN6 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246207 | 0.88 | SHBG (0.63) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL4246211 | 0.88 | SHBG (0.63) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL5143409 | 0.87 | SHBG (0.74) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL10054959 | 0.83 | SHBG (0.70) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL4083803 | 0.83 | SHBG (0.70) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL4075005 | 0.83 | HSD17B1 (0.69) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL10439769 | 0.82 | HSD17B1 (0.70) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL4082465 | 0.82 | SHBG (0.68) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL4827791 | 0.82 | CYP19A1 (1.00) | CYP19A1ESR1ESR2SHBGSTS | |
| SCHEMBL8410921 | 0.82 | CYP19A1 (0.80) | CYP19A1ESR1ESR2STSHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192258-A1 | Antiangiogenic agents | AGOSTON GREGORY E (US) | 2005-09-01 | — | — | US | claimed |
| US-8273383-B2 | Administration of 2-methoxyestradiol or it derivatives such as colchicine or combretastatin A-4; for treating and/or preventing a pregnancy related disease; safer and more effective | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| EP-1906969-A4 | METHODS FOR TREATING AND DIAGNOSING COMPLICATIONS OF PREMATURE BIRTH | CHILDRENS MEDICAL CENTER (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-1773349-A4 | METHODS AND COMPOSITIONS FOR TREATMENT OF PREECLAMPSIA | CHILDRENS MEDICAL CENTER (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080160105-A1 | Methods and Compositions For Treatment of Preeclampsia | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1906969-A2 | METHODS FOR TREATING AND DIAGNOSING COMPLICATIONS OF PREMATURE BIRTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2008-04-09 | — | — | EP | disclosed |
| EP-1773349-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PREECLAMPSIA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2007011926-A2 | METHODS FOR TREATING AND DIAGNOSING COMPLICATIONS OF PREMATURE BIRTH | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2007-01-25 | — | — | WO | disclosed |
| US-7135581-B2 | Antiangiogenic agents | ENTREMED, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| WO-2005110462-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF PREECLAMPSIA | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050192258-A1 | Antiangiogenic agents | AGOSTON GREGORY E (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192258-A1 | Antiangiogenic agents | VEGFA, PGF, TEK | CYP19A1 21/4885ESR1 150/4885ESR2 13/4885 |
| US-20080160105-A1 | Methods and Compositions For Treatment of Preeclampsia | PGF, SHBG, HSD17B11 | CYP19A1 26/4885ESR1 107/4885ESR2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.